AL amyloidosis
MONDO:0019438AL Amyloidosis is a plasma cell disorder characterized by the aggregation and deposition of insoluble amyloid fibrils derived from misfolding of monoclonal immunoglobulin light chains usually produced by a plasma cell tumor. It usually presents as primary systemic amyloidosis (PSA) with multiple organ involvement and less frequently as primary localized amyloidosis (PLA) restricted to a single organ.
Also known as: Light-chain amyloidosis, primary amyloidosis, Light chain amyloidosis, amyloidosis AL, amyloidosis primary systemic, primary AL amyloidosis, primary systemic AL amyloidosis, primary systemic amyloidosis
104 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Heart scan tracer may reveal Chemo's effect on amyloid buildup
Disease control TerminatedThis pilot study tests whether a special PET scan tracer called 18F florbetapir can detect changes in amyloid protein deposits in the heart of people with AL cardiac amyloidosis who are receiving chemotherapy. Four participants will have a PET/CT scan before starting chemotherapy…
Phase: PHASE4 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental NK cell therapy for blood cancers hits early hurdle
Disease control TerminatedThis early-stage study tested a new drug called SAR445514, which helps the body's natural killer (NK) cells attack cancer cells in people with multiple myeloma or light-chain amyloidosis that had returned or stopped responding to other treatments. The study was terminated early, …
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental antibody trial for rare heart disease halted early
Disease control TerminatedThis phase 3 study tested an experimental drug called birtamimab in 208 people with advanced AL amyloidosis, a rare disease where abnormal proteins damage organs like the heart. Participants received either birtamimab or a placebo, plus standard chemotherapy. The goal was to see …
Phase: PHASE3 • Sponsor: Prothena Biosciences Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Promising drug combo for rare amyloidosis hits snag: trial ends early
Disease control TerminatedThis study tested a drug called ixazomib plus dexamethasone against other standard treatments for people with relapsed AL amyloidosis, a rare disease where abnormal proteins build up in organs. The trial aimed to see if the combination improved blood markers and slowed heart or k…
Phase: PHASE3 • Sponsor: Millennium Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:13 UTC